Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
US |
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
2.4m USD | -0 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 459 134.4 | |
US |
Eli Lilly and Co
NYSE:LLY
|
697.9B USD | 60.2 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 33 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
357.8B USD | 11.8 | ||
US |
Merck & Co Inc
NYSE:MRK
|
323.8B USD | 33.4 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 140.6 | ||
CH |
Novartis AG
SIX:NOVN
|
179.8B CHF | 9.7 | ||
CH |
Roche Holding AG
SIX:ROG
|
172.7B CHF | 8.6 | ||
US |
Pfizer Inc
NYSE:PFE
|
155.7B USD | 11 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.